CDC42 and colorectal cancer: In keeping with the results presented here, one of these molecules, AZA197 suppressed primary colon cancer growth in vivo and prolonged survival in SW620 tumor xenografts, indicating the therapeutic potential of this inhibitor based on targeting CDC42 GTPase activity in colorectal cancer.